Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

M. Teresa Valenzuela; R. Jake Jacobs; Oscar Arteaga; Maria S. Navarrete; Allen S. Meyerhoff; Bruce L. Innis

doi:10.1016/j.vaccine.2005.03.021

Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

M. Teresa Valenzuela, R. Jake Jacobs^*, Oscar Arteaga, Maria S. Navarrete, Allen S. Meyerhoff, Bruce L. Innis

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.

Original language	English
Pages (from-to)	4110-4119
Number of pages	10
Journal	Vaccine
Volume	23
Issue number	32
DOIs	https://doi.org/10.1016/j.vaccine.2005.03.021
State	Published - 14 Jul 2005

Bibliographical note

Funding Information:
We thank the following groups and individuals: the Ministry of Health, for supporting our access to data required to conduct this analysis; Dr. Betsy Hunter and Lorena Calabrán, Hospital Luis Calvo Mackenna, for providing information on children with acute liver failure; the Infectious Disease Hospital, Hospital Lucio Cóórdoba, for assisting the cost analysis of adult patients; and CVD-Chile, for assisting the cost analysis of pediatric patients. This study was supported in part by an research grant from GlaxoSmithKline Biologicals to Capitol Outcomes Research Inc. Drs. Navarrete and Innis are employees of GlaxoSmithKline.

Keywords

Cost and cost analysis
Hepatitis A
Vaccination

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2005.03.021

Cite this

@article{40645a7b5290401baa7facf214eb6cc3,

title = "Cost-effectiveness of universal childhood hepatitis A vaccination in Chile",

abstract = "Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.",

keywords = "Cost and cost analysis, Hepatitis A, Vaccination",

author = "Valenzuela, {M. Teresa} and Jacobs, {R. Jake} and Oscar Arteaga and Navarrete, {Maria S.} and Meyerhoff, {Allen S.} and Innis, {Bruce L.}",

note = "Funding Information: We thank the following groups and individuals: the Ministry of Health, for supporting our access to data required to conduct this analysis; Dr. Betsy Hunter and Lorena Calabr{\'a}n, Hospital Luis Calvo Mackenna, for providing information on children with acute liver failure; the Infectious Disease Hospital, Hospital Lucio C{\'o}{\'o}rdoba, for assisting the cost analysis of adult patients; and CVD-Chile, for assisting the cost analysis of pediatric patients. This study was supported in part by an research grant from GlaxoSmithKline Biologicals to Capitol Outcomes Research Inc. Drs. Navarrete and Innis are employees of GlaxoSmithKline.",

year = "2005",

month = jul,

day = "14",

doi = "10.1016/j.vaccine.2005.03.021",

language = "English",

volume = "23",

pages = "4110--4119",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "32",

}

TY - JOUR

T1 - Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

AU - Valenzuela, M. Teresa

AU - Jacobs, R. Jake

AU - Arteaga, Oscar

AU - Navarrete, Maria S.

AU - Meyerhoff, Allen S.

AU - Innis, Bruce L.

N1 - Funding Information: We thank the following groups and individuals: the Ministry of Health, for supporting our access to data required to conduct this analysis; Dr. Betsy Hunter and Lorena Calabrán, Hospital Luis Calvo Mackenna, for providing information on children with acute liver failure; the Infectious Disease Hospital, Hospital Lucio Cóórdoba, for assisting the cost analysis of adult patients; and CVD-Chile, for assisting the cost analysis of pediatric patients. This study was supported in part by an research grant from GlaxoSmithKline Biologicals to Capitol Outcomes Research Inc. Drs. Navarrete and Innis are employees of GlaxoSmithKline.

PY - 2005/7/14

Y1 - 2005/7/14

N2 - Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.

AB - Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.

KW - Cost and cost analysis

KW - Hepatitis A

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=20444436017&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.03.021

DO - 10.1016/j.vaccine.2005.03.021

M3 - Article

C2 - 15964479

AN - SCOPUS:20444436017

SN - 0264-410X

VL - 23

SP - 4110

EP - 4119

JO - Vaccine

JF - Vaccine

IS - 32

ER -

Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this